Biosimilar Medicines Conference
FUELLED BY THE PAST, GEARING UP FOR THE FUTURE

HILTON AMSTERDAM AIRPORT SCHIPHOL

3-4 APRIL 2025

 

Medicines for Europe is delighted to welcome you to the 2025 Biosimilar Medicines Conference, where thought leaders and agents of change from industry, policymakers, regulators, patients and healthcare professionals gather each year to advance the policy agenda around patient access, biosimilar medicines, pharmaceuticals and health.

The growing importance of biological therapies continues to positively impact patient health as well as profoundly challenge healthcare financing, organisation and infrastructure, and supply chains.

Biosimilar policies have contributed to making biosimilar medicines use a high-impact intervention, delivering value across the healthcare community.

This conference will serve as a platform for robust discussions on key topics such as access, development, market competition, progress in regulatory science, and the critical role biosimilar medicines play in reshaping healthcare landscapes and industrial ecosystems.

Among key questions and perspectives, the following will be addressed:

  • What have been the enablers and winning strategies for enhancing access to biotherapies? What tools can help map inefficiency and access gaps to better guide healthcare investments?
  • How can a balanced approach be achieved in terms of market regulativos and competition dynamics? Short-term wins and longer-term health objectives?
  • How are patients and healthcare professionals contributing to biosimilar adoption in new therapy areas?
  • How is horizon scanning impacting payers’ and regulators’ focus? How can streamlining of biosimilar development foster competition across a broader range of biological medicines?
  • What would be the priority actions to kick off discussions on bringing Advanced Therapies biosimilars to the European market?
  • What does the global biotech ecosystem look like for biosimilar R&D and Manufacturing? Where does Europe stand regarding competitiveness?

WFIPP, represented by our President Mary Lynne van Poelgeest, has a key role in the discussions.

 

For more information, please click here